Merit

For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

PEG-MGF

Also known as: PEGylated Mechano Growth Factor

PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the distinct 24-amino-acid C-terminal E-peptide encoded by the IGF-1Ec splice variant (IGF-1Eb in rodents) that is transiently upregulated in muscle after mechanical loading or damage. MGF is related to but pharmacologically distinct from mature IGF-1 and IGF-1 LR3. Pegylation extends its half-life from minutes to several hours, and the compound is marketed as a research chemical for muscle repair protocols. It is not FDA-approved for any indication.

Real-time market data

Pricing for PEG-MGF

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$20.49/mg

range $12.60–$48.50/mg

Sellers

18

from $0.00

45-day trend

+11.1%

vs 45-day avg $/mg

16 of 18 sellers have a current price· 9 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for PEG-MGF

13 third-party tests across 6 vendors. Each card links to the full report.

All 13 COAs for PEG-MGF →
Measured purity 99.1%–99.9% across 7 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.89 %
Mar 2026
Janoshik Analytical Limited · HPLC

For

PEG-MGF with Trehalose

by Skye Peptides· batch PMG26-05-001

Aggregated · 3rd-party listing
99.72 %
Feb 2026
MDx BioAnalytical Laboratory Strong · HPLC

For

PEG-MGF

by BioLongevity Labs· batch QC260699

✓ Vendor-published
99.22 %
Feb 2026
Janoshik Analytical Limited

For

PEG-MGF

by Ruo Bio

COA on file
✓ Vendor-published
99.80 %
Jan 2026
Bioviridian Moderate

For

PEG-MGF

by Ion Peptide· batch PMGF-010226

COA on file
Aggregated · 3rd-party listing
99.80 %
Dec 2025
Bioviridian Moderate

For

PEG-MGF

by Ion Peptide· batch PMGF-121325

✓ Vendor-published
99.45 %
Oct 2025
MZ Biolabs Moderate

For

PEG-MGF

by Sports Technology Labs· batch 2025-10-06

COA on file
Aggregated · 3rd-party listing
99.10 %
Aug 2025
Freedom Diagnostics Moderate · HPLC

For

PEG-MGF

by Simple Peptide· batch PEGM08252025-J

Aggregated · 3rd-party listing
99.80 %
Bioviridian Moderate

For

PEG-MGF

by Ion Peptide· batch PMGF-010226

Aggregated · 3rd-party listing
—
Mar 2026

Purity not on file

Janoshik Analytical Limited

For

PEG-MGF with Trehalose

by Skye Peptides· batch PMG26-05-001

Aggregated · 3rd-party listing
—
Mar 2026

Purity not on file

Janoshik Analytical Limited

For

PEG-MGF with Trehalose

by Skye Peptides· batch PMG26-05-001

Aggregated · 3rd-party listing
—
Jun 2025

Purity not on file

Janoshik Analytical Limited

For

PEG-MGF

by Peptidegurus· batch cmojgr60i002i9grxmefx6ikp

✓ Vendor-published
—

Purity not on file

Lab unknown

For

PEG-MGF

by Moglabs

COA on file
✓ Vendor-published
—

Purity not on file

Lab unknown

For

PEG-MGF

by Ruo Bio

COA on file
Research depth

11 citations indexed for PEG-MGF

All research on PEG-MGF →

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

rct · 2018

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).

rct · 2018

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events

Study · 2017

The Generation of Dehydroalanine Residues in Protonated Polypeptides: Ion/Ion Reactions for Introducing Selective Cleavages

We examine a gas-phase approach for converting a subset of amino acid residues in polypeptide cations to dehydroalanine (Dha). Subsequent activation of the modified polypeptide ions gives rise to specific cleavage N-terminal to the Dha residue.

rct · 2016

A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.

rct · 2015

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection.